Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.

R D'Haens, Geert; J Sandborn, William; V Loftus, Edward; B Hanauer, Stephen; Schreiber, Stefan; Peyrin-Biroulet, Laurent; Panaccione, Remo; Panés, Julián; Baert, Filip; Colombel, Jean-Frederic; Ferrante, Marc; Louis, Edouard; Armuzzi, Alessandro; Zhou, Qian; S Goteti, Venkata; M Mostafa, Nael; T Doan, Thao; Petersson, Joel; Finney-Hayward, Tricia; P Song, Alexandra; M Robinson, Anne; Danese, Silvio

doi:10.1053/j.gastro.2022.01.044

Public

Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.

Shared by NobleBlocks on Jun 1, 2022 • 12:00 AM UTC

Authors:

Geert R D'Haens

William J Sandborn

Edward V Loftus

Abstract

BACKGROUND & AIMS: Dose-optimization strategies for biologic therapies in Crohn's disease (CD) are not well established. The SERENE CD (Study of a Novel Approach to Induction and Maintenance Dosing With Adalimumab in Patients With Moderate to Severe Crohn's Disease) trial evaluated higher vs standar...

Subject

Biologic Agent

Inflammatory Bowel Disease

Monoclonal Antibody

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!